Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Feb 01, 2008
Appendix 3B - allotment of rights issue shares
Jan 31, 2008
Neuren Appendix 4C December 2007
Jan 31, 2008
Results of Rights Issue
Jan 21, 2008
US Department of Defense Approves NNZ2566 Funding
Jan 17, 2008
Glypromate trial recruits 100th patient
Jan 09, 2008
Neuren Confirms Despatch of Rights Issue Offer Documents
Jan 09, 2008
Section 708AA Notice
Previous
1
2
3
4
5
6